國誠通發展集團(00217.HK)與國藥控股(01099.HK)附屬訂融資租賃協議 涉資1.8億人幣
國誠通發展集團(00217.HK)公佈,附屬誠通融資租賃向最大股東爲國藥控股(01099.HK)的國藥控股(中國)融資租賃,購買發電、配電、防火等設備,並將該等設施回租予國藥控股(中國)融資租賃,爲期兩年。
購買價格1.7億元人民幣(下同),乃由誠通融資租賃與國藥控股(中國)融資租賃經參考原售後回租協議項下,未償還租賃本金總額約1.94億元後協定。租賃付款總額估計約爲1.79億元。承租人有權以1元象徵式代價回購該等設施。預期誠通融資租賃將賺取約1,061萬元的收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.